aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Novoron Bioscience is a biotechnology company dedicated to developing pharmaceutical therapies aimed at regenerating the central nervous system. Founded with a mission to restore the brain and spinal cord's regenerative capacity, Novoron focuses on innovative treatments that address nerve damage and neurodegenerative diseases. Their core products are designed to enhance the natural healing processes within the central nervous system, offering new hope for patients with conditions that currently have limited treatment options.
Notable figures affiliated with Novoron include leading scientists and researchers in the field of neuroregeneration. The company has garnered attention from prominent investors in the biotech sector, contributing to its rapid development and research capabilities. Key achievements include significant advancements in preclinical studies, positioning Novoron as a promising player in the neurotherapeutics market. Overall, Novoron Bioscience is making impactful strides towards revolutionizing treatments for central nervous system injuries and diseases.
Operating Status
Active
Ownership Type(s)
Venture Capital, Private Equity
Main Product(s)
Pharmaceutical Therapies
Technology
Biotech
Tags
Biotech, Healthtech
Model Types
Biotech
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise
Geographic Exposure
Global
When was Novoron Bioscience founded?
Novoron Bioscience was founded in 2014.
Where is Novoron Bioscience’s headquarters located?
Novoron Bioscience’s headquarters is located in San Diego, CA, US.
When was Novoron Bioscience’s last funding round?
Novoron Bioscience’s most recent funding round was for $9.5M (USD) in December 2022.
How many employees does Novoron Bioscience have?
Novoron Bioscience has 5 employees as of Feb 5, 2024.
How much has Novoron Bioscience raised to-date?
As of July 05, 2023, Novoron Bioscience has raised a total of $13.8M (USD) since Dec 10, 2022.
Add Comparison
Total Raised to Date
$13.8M
USD
Last Update Dec 10, 2022
Last Deal Details
$9.5M
USD
Dec 10, 2022
Seed
Total Employees Over Time
5
As of Feb 2024
Novoron Bioscience Address
7770 Regents Road
# 113319
San Diego,
California
92122
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts